Cargando…
Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy
Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. Although several HCV protease/polymerase inhibitors were recently approved by U.S. FDA, the combination of antivirals targeting multiple processes of HCV lifecycle would optimize anti-HCV therapy and against potential drug-resist...
Autores principales: | Cao, Lin, Chen, Jizheng, Wang, Yaxin, Yang, Yuting, Qing, Jie, Rao, Zihe, Chen, Xinwen, Lou, Zhiyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338621/ https://www.ncbi.nlm.nih.gov/pubmed/29542010 http://dx.doi.org/10.1007/s13238-018-0521-z |
Ejemplares similares
-
Current progress in antiviral strategies
por: Lou, Zhiyong, et al.
Publicado: (2014) -
Protein Inhibitor of Activated STAT2 Restricts HCV Replication by Modulating Viral Proteins Degradation
por: Guo, Jing, et al.
Publicado: (2017) -
Generation of fluorescent HCV pseudoparticles to study early viral entry events- involvement of Rab1a in HCV entry
por: Bhattacharjee, Chayan, et al.
Publicado: (2022) -
Targeting HCV Entry For Development of Therapeutics
por: Wong-Staal, Flossie, et al.
Publicado: (2010) -
Lysosomotropic agents as HCV entry inhibitors
por: Ashfaq, Usman A, et al.
Publicado: (2011)